Cargando…

P1010: PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS HAVE INCREASED NUMBERS OF MYELOID-DERIVED SUPPRESSOR CELLS, AND DECITABINE MAY HAVE A SIGNIFICANT THERAPEUTIC EFFECT IN MPN PATIENTS WITH HIGH MDSCS

Detalles Bibliográficos
Autores principales:	Feng, Qiutian, Hu, Shiwei, Xiang, Danhong, Zhang, Xinlu, Zhang, Lan, Wang, Shengjie, Zhu, Xiaoqiong, Huang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431309/ http://dx.doi.org/10.1097/01.HS9.0000970944.20308.82

Ejemplares similares

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
por: Mesa, Ruben, et al.
Publicado: (2016)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
por: Bhuria, Vikas, et al.
Publicado: (2022)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

PB2206: PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY
por: Xiang, Danhong, et al.
Publicado: (2023)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells (MDSCs) in Haematology
por: Bizymi, Nikoleta, et al.
Publicado: (2021)

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)
por: Price, Gregory L., et al.
Publicado: (2014)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
por: Byun, Ja Min, et al.
Publicado: (2022)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
por: Harrison, Claire N., et al.
Publicado: (2017)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
por: Gao, Xidan, et al.
Publicado: (2021)

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis
por: Aoyama, Yumi, et al.
Publicado: (2019)

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Patients with myeloproliferative neoplasms and COVID‐19 have increased rates of arterial thrombosis
por: Leiva, Orly, et al.
Publicado: (2022)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023)

Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy
por: He, Wei, et al.
Publicado: (2016)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
por: Yadav, Ruchi, et al.
Publicado: (2023)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward
por: Okła, Karolina
Publicado: (2023)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms
por: Viaud, Manon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rttof5j6ij85inf93aqhejj4qg